FDA shortage: Liraglutide Injection (Injection) — Currently in Shortage
Liraglutide is on the FDA drug shortage list as of Oct 14, 2026.
What changed & why it matters
MedSpaRadar recorded an FDA drug-shortage update at the federal level, dated June 11, 2026, in the GLP-1 Compounding category, naming Liraglutide.
FDA shortage status for Liraglutide can affect the conditions for compounding under sections 503A and 503B. A shortage listing alone does not authorize compounding; the applicable conditions differ between those pathways. Manufacturer-reported availability of a presentation does not establish that FDA has resolved the shortage. Check the current drug-specific FDA record and applicable compounding conditions.
- Type
- FDA Drug Shortages
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Substance
- Liraglutide
- Recorded
- June 11, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
Review pending — this item’s source changed; the summary below is being re-checked.
FDA Drug Shortages · primary source ↗
Get regulatory changes as they publish
We scan all 50 state legislatures daily, plus the FDA and the Federal Register. Free weekly Brief — what changed, in plain language, with the source.
Free · unsubscribe in one click · we never sell your address
Related alerts
- Source qualification pending
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- Source qualification pending
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA Warning Letter: Fresenius Kabi Compounding, LLC (Drugs)
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.